Brain-derived neurotrophic factor

Therapeutic Solutions International Spin-Off Campbell Neurosciences Identifies Mechanism of Action for Umbilical Cord Blood Derived NarcoStem™ Drug Rehabilitation Product

Retrieved on: 
Monday, April 19, 2021
Branches of biology, Developmental neuroscience, Growth factors, Neurotrophic factors, Peptide hormones, Brain-derived neurotrophic factor, Immunotherapy

This is not something that ketamine, CBD, or psilocybin are capable of doing.

Key Points: 
  • This is not something that ketamine, CBD, or psilocybin are capable of doing.
  • Demonstration that BDNF mediates therapeutic activities of NarcoStem helps accelerate the timeline for clinical translation of this inhalable therapeutic.
  • Unfortunately, it is almost impossible to provide recombinant BDNF directly into the brain due to its size and half live.
  • "\nTherapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases.

HumanN Launches New SuperBeets® Memory & Focus Chews to Support Brain Health

Retrieved on: 
Thursday, March 25, 2021
Branches of biology, Developmental neuroscience, Growth factors, Neurotrophic factors, Peptide hormones, Neurochemistry, Brain-derived neurotrophic factor, Brain, Resveratrol

SuperBeetsMemory & Focus is a unique supplement that contains clinically-studied polyphenol compounds to support two aspects of brain health: brain blood flow and BDNF.

Key Points: 
  • SuperBeetsMemory & Focus is a unique supplement that contains clinically-studied polyphenol compounds to support two aspects of brain health: brain blood flow and BDNF.
  • Blood flow to the brain, along with Brain-Derived Neurotrophic Factor (BDNF) - a key protein found in the brain - are important in promoting overall cognitive health.
  • SuperBeetsMemory & Focus features a highly pure form of Resveratrol produced through a unique fermentation process, along with a patented coffee fruit extract that have been clinically shown to help promote brain blood flow and support brain health, respectively.
  • Humann'sfull catalog of products, including the new SuperBeets Memory & Focus Chews is available online and on Amazon.

Aptinyx to Participate in Upcoming Investor Conferences

Retrieved on: 
Monday, February 22, 2021
Research, FDA, Clinical trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Branches of biology, Biology, Neuroplasticity, Glutamate, Molecular neuroscience, Cell signaling, NMDA receptor, Synaptic plasticity, Brain-derived neurotrophic factor

Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders.

Key Points: 
  • Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders.
  • Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulaterather than block or over-activateNMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication.
  • The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment associated with Parkinsons disease.
  • Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders.

Study: Combining Brain Training and Walking Helps Heart Failure Patients

Retrieved on: 
Tuesday, October 20, 2020
Branches of biology, Heart diseases, Heart failure, Organ failure, RTT, Brain-derived neurotrophic factor

An estimated 6.5 million Americans are diagnosed with heart failure, with 960,000 new cases each year.

Key Points: 
  • An estimated 6.5 million Americans are diagnosed with heart failure, with 960,000 new cases each year.
  • The researchers measured quality of life using the Kansas City Cardiomyopathy Questionnaire, a disease-specific index for heart failure.
  • The 6-Minute Walk Test is a simple assessment used in heart failure thats predictive of future health outcomes.
  • In prior studies of BrainHQ among heart failure patients , researchers found significant gains in global cognition, processing speed, verbal memory, and learning, as well as significant gains that showed re-normalized BDNF (a blood marker of brain health).

Organifi® Celebrates 6th Anniversary with Announcement of Packaging Rebrand to Highlight Quality Ingredients

Retrieved on: 
Monday, October 19, 2020
Branches of biology, Nutrition, Superfood, Brain-derived neurotrophic factor, Cortisol, Juice, Psychological stress

Organifi's suite of products is now inclusive of more than 10 superfood blends, all with high-quality, plant-based ingredients and research-backed formulations.

Key Points: 
  • Organifi's suite of products is now inclusive of more than 10 superfood blends, all with high-quality, plant-based ingredients and research-backed formulations.
  • Organifi Green Juice - Essential superfoods that support healthy cortisol levels to reduce stress and reset your morning while aiding in weight management.
  • Organifi Gold - A soothing blend of superfoods, including turmeric, to reshape your evening ritual, supporting rest and relaxation.
  • Organifi Pure - A blend of superfoods designed to improve gut health, promote healthy BDNF levels and help support normal mental clarity.

Relmada Therapeutics Presents Clinical Data on Increased BDNF Plasma Levels in Subjects Treated with REL-1017

Retrieved on: 
Wednesday, December 12, 2018
Health, Clinical research, Design of experiments, Medical research, Growth factors, Nursing research, Brain-derived neurotrophic factor, Developmental neuroscience, Placebo-controlled study, Antidepressant, Clinical trial

Relmada is currently evaluating REL-1017 in a Phase 2 clinical trial assessing tolerability, safety and antidepressant efficacy in patients with MDD.

Key Points: 
  • Relmada is currently evaluating REL-1017 in a Phase 2 clinical trial assessing tolerability, safety and antidepressant efficacy in patients with MDD.
  • The BDNF plasma level data presented were derived from a single-site, randomized, double-blind, placebo-controlled Phase 1 clinical trial of REL-1017 administered orally for 10 days to healthy volunteers admitted for 14 days to a Clinical Research Unit (CRU) (NCT03638869).
  • The study findings showed that the administration of REL-1017 significantly increased BDNF plasma levels in healthy subjects compared to placebo, ranging from twice to 17 times the pre-treatment BDNF levels.
  • Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

BrainStorm Announces Grant of a New European Patent for NurOwn®

Retrieved on: 
Wednesday, July 25, 2018
Biology, Developmental neuroscience, Neurotrophic factors, Peptide hormones, Stem cells, Brain-derived neurotrophic factor, Amyotrophic lateral sclerosis, Mesenchymal stem cell, Amyotrophic lateral sclerosis research

This patent provides protection for NurOwn in Europe until 2029.

Key Points: 
  • This patent provides protection for NurOwn in Europe until 2029.
  • The allowed claims cover methods of treating amyotrophic lateral sclerosis (ALS) using mesenchymal stem cells that secrete neurotrophic factors, including Brain derived neurotrophic factor (BDNF).
  • The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University.
  • NurOwn has been administered to over 70 patients with ALS in clinical trials conducted in the United States and Israel.

Neurotrope to Present Additional Phase 2 Data at the Alzheimer's Association International Conference (AAIC) 2018 Meeting

Retrieved on: 
Monday, July 2, 2018
Biology, Cell biology, Cell signaling, Developmental neuroscience, Growth factors, Neurotrophic factors, Peptide hormones, Brain-derived neurotrophic factor, NMDA receptor, Synaptogenesis, Insulin-like growth factor 1, MTOR

This has been demonstrated in pre-clinical models because our target PKC epsilon activates synaptic growth factors like BDNF, NGF and IGF-1.

Key Points: 
  • This has been demonstrated in pre-clinical models because our target PKC epsilon activates synaptic growth factors like BDNF, NGF and IGF-1.
  • The data indicate that PKC's synaptogenesis efficacy cannot occur when the NMDA receptor is blocked.
  • We are excited to be presenting this new data at this prestigious international forum" stated Dr. Daniel Alkon, President and Chief Scientific Officer of Neurotrope.
  • Clinical trial data are subject to differing interpretations, and regulatory agencies, medical and scientific experts and others may not share the Company's views of the Phase 2 data.